Cougle stated that heavy winter storm impacts in January will likely put Q1 2026 results "largely in line with Q4," but expressed confidence that full year 2026 goals remain within reach. She expects ...
Cash and Investments -- $301.8 million as of December 31, 2025, sufficient to fully fund current Phase III HCV and new HEV programs through 2027. Phase III HCV Trials -- C BEYOND enrollment completed ...
Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outs ...
March 5, 2026) - Cabral Gold Inc. (TSXV: CBR) (OTCQX: CBGZF)("Cabral" or the "Company") is pleased to provide a construction ...
"We are also seeing improvement in US biotech funding, as well as higher M&A and IPO activity, which are leading indicators ...
Good afternoon, everyone, and welcome to the Atea Pharmaceuticals' Fourth Quarter 2025 Financial Results and Business Update Conference Call. [Operator Instructions] I would now like to turn the call ...
Total revenue -- $128.6 million in the fiscal fourth quarter ended Dec. 31, 2025, with primary growth from DEFENCATH and the first full-quarter contribution from the Melinta portfolio. Fiscal 2026 ...
Key Financial Developments 2025 Revenues of €180.0 million, down 1% yoy (2024: €181.9 million), with improved momentum in H2Gross margin improved to 51.3% (2024: 50.9%), due to an improved product ...
Bilibili Inc. ('Bilibili” or the 'Company”) (Nasdaq: BILI and HKEX: 9626), an iconic brand and a leading video community for ...
COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, provides business up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results